Oncobiomix Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-16.
Oncobiomix Inc. filed a Form D notice of an exempt securities offering with the SEC on September 16, 2026. The filing reports $100K sold. Its industry group is Other Health Care. It names Michael Liss (Executive Officer, Director) (SEC Form D, September 16, 2026).
Oncobiomix Inc. raised on Sep 16. 125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Oncobiomix Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Oncobiomix Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Oncobiomix Inc.
Free to see. No signup.
More on the people and the money behind Oncobiomix Inc., from the filings we hold.
Other Health Care raises by companies based in Texas, filed within 90 days of this one, largest first.
Get an email when Oncobiomix Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Oncobiomix Inc. raises, hires or launches. No email unless you switch it on.
Watch Oncobiomix Inc. →Get the full cited report on Oncobiomix Inc.
What the filing shows about Oncobiomix Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Oncobiomix Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Oncobiomix Inc.'s address as 3463 Magic Drive, Suite T7, San Antonio, TX 78229.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Oncobiomix Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Oncobiomix Inc. is a registered filer with the SEC (CIK 1998501) and has filed since 2023-11-06. 2 filings are on record, the latest on 2026-09-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Oncobiomix Inc.'s Form D of 2026-09-16 names Michael Liss as its officers, directors or promoters.
Its new offerings report $250K sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 866 filings in Other Health Care, totalled by week. The dot is this raise, $100K, on the same scale — one filing against the whole group's total, so it sits low by construction.
A portion of the proceeds will be used to pay compensation to some of the Executive Officers named in response to item 3 above.
Michael Liss is named as Executive Officer and Director on the Form D that Oncobiomix Inc. filed with the SEC on 16 September 2026, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2026-09-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Oncobiomix Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Oncobiomix Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oncobiomix Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Oncobiomix Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Oncobiomix Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Oncobiomix Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-09-14 · Health care raises, week of 2026-09-14
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/oncobiomix-inc-form-d-000001